astrazeneca hit by drug failure shares in anglo swedish drug have closed down 8% in uk trade after the failure of its iressa drug in a major clinical trial. i am determined to improve our development and regulatory performance, restore confidence in the company and value to shareholders, said chief executive tom mckillop. tarceva made by osi pharmaceuticals, genentech and roche has already proved to be successful in helping prolong the life of lung cancer patients. meanwhile, another of its major money spinners cholesterol drug crestor is facing mounting safety concerns. and we've got risks on crestor, said nick turner, analyst at brokers jefferies.